Principal Financial Group’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.01M Buy
10,601
+869
+9% +$79.1K ﹤0.01% 1938
2026
Q1
$937K Buy
9,732
+1,245
+15% +$125K ﹤0.01% 1954
2025
Q4
$826K Buy
8,487
+2,560
+43% +$220K ﹤0.01% 1984
2025
Q3
$422K Buy
+5,927
New +$395K ﹤0.01% 2078
2025
Q2
Sell
-5,460
Closed -$287K 2269
2025
Q1
$287K Buy
5,460
+20
+0.4% +$1.12K ﹤0.01% 2001
2024
Q4
$299K Buy
5,440
+546
+11% +$28.7K ﹤0.01% 2034
2024
Q3
$246K Buy
+4,894
New +$226K ﹤0.01% 2067

Other funds holding IRMD

Principal Financial Group's IRMD Position: Q2 2026 in Review

Principal Financial Group increased its iRadimed (IRMD) stake by 8.9% in Q2 2026, buying an estimated $79.1K and bringing the position to 10,601 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1938.

Principal Financial Group first reported a position in IRMD in Q3 2024 and has held it in 7 quarters since. 213 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Principal Financial Group held 10,601 shares of iRadimed worth $1.01M as of Q2 2026.
  • Principal Financial Group bought 869 iRadimed shares in Q2 2026, an estimated $79.1K.
  • iRadimed made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1938 holding.
  • Principal Financial Group first reported a position in iRadimed in Q3 2024 and has held it in 7 quarters since.
  • 213 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.